Thoracic oncology and neuroendocrine malignancies
Research activity is concentrated in aggressive thoracic cancers, including small cell lung cancer, extensive-stage extrapulmonary small cell carcinoma, and pulmonary large-cell neuroendocrine carcinoma. The funded studies also address treatment approaches in malignant pleural mesothelioma, with attention to disease control and post-surgical outcomes.
- Small cell lung cancer
- Extrapulmonary small cell carcinoma
- Large-cell neuroendocrine carcinoma
- Malignant pleural mesothelioma
These programmes focus on immunotherapy-based and platinum-based treatment strategies in advanced thoracic disease.
Non-small cell lung cancer with ALK rearrangement
The sponsor supports studies in locally advanced stage III non-small cell lung cancer, particularly in patients with anaplastic lymphoma kinase positive disease. This area reflects interest in molecularly defined lung cancer and preoperative treatment settings.
- ALK-positive NSCLC
- Locally advanced stage III disease
- Neoadjuvant treatment
The clinical focus is on improving tumour response before surgery in biomarker-selected lung cancer.
Urothelial carcinoma
Another key area is advanced and metastatic urothelial carcinoma, with studies centred on disease control after prior systemic therapy. This reflects sustained interest in treatment options for recurrent bladder and urinary tract malignancies.
- Metastatic urothelial carcinoma
- Post-treatment maintenance therapy
- Advanced urinary tract cancer
The funded research addresses patients with disease progression after earlier immunotherapy and chemotherapy.
Rectal cancer and gastrointestinal immunotherapy
The portfolio includes locally advanced rectal cancer with pMMR/MSS or MSI-low features, exploring consolidation approaches after standard chemoradiation. This indicates involvement in colorectal cancer subtypes where immune responsiveness is limited.
- Locally advanced rectal cancer
- pMMR/MSS tumours
- MSI-low disease
- Consolidation treatment
The research interest lies in refining treatment pathways for rectal cancer patients after chemoradiation.
